Intersect Ent, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2017, First Quarter and Full Year of 2018
January 08, 2018 at 06:30 pm IST
Intersect ENT, Inc. Provided earnings guidance for the fourth quarter and full year ended December 31, 2017. For the quarter, the company’s expected revenue to be in the range of $29.3 to $29.5 million, an increase of 21-22% compared to $24.2 million for the fourth quarter of 2016.
For the full year, the company’s expected revenue to be in the range of $96.1 to $96.3 million, an increase of 22% compared to $78.7 million for 2016.
The company forecasts full year 2018 revenue in the range of $111 to $116 million, which would represent an increase of 15%-20% over 2017 and which includes an estimated 8% contribution from SINUVA product sales.
The company forecasts for first quarter 2018 revenue is in the range of $23.2 to $23.7 million, and the company continues to expect to launch SINUVA commercially in the second quarter of 2018.